The future of regulatory toxicology: Impact of the biotechnology revolution

Toxicological Sciences

Volumn 75, Issue 2, 2003, Pages 236-248

  MacGregor, James T ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Biomarkers; Genomics; Haplotype; Metabonomics; Microarray; Polymorphism; Proteomics; Toxicity; Validation

Indexed keywords

BIOLOGICAL MARKER; DNA;

BIOCHEMISTRY; BIOINFORMATICS; BIOLOGICAL MONITORING; BIOTECHNOLOGY; CARCINOGENESIS; CELL DAMAGE; CELL DEATH; CELL FUNCTION; CELL STRUCTURE; CYTOLOGY; DISEASE PREDISPOSITION; DNA SEQUENCE; GENE MAPPING; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOMICS; HAPLOTYPE; HOMEOSTASIS; HUMAN; IMAGING SYSTEM; MATHEMATICAL COMPUTING; MOLECULAR BIOLOGY; MOLECULAR EVOLUTION; MOLECULAR GENETICS; MUTAGENESIS; NON INVASIVE MEASUREMENT; NONHUMAN; PATHOLOGY; PREDICTION; PROTEOMICS; REVIEW; SEQUENCE ANALYSIS; TOXICOLOGY;

ANIMALS; BIOTECHNOLOGY; DRUG AND NARCOTIC CONTROL; GOVERNMENT REGULATION; HUMANS; MOLECULAR BIOLOGY; TOXICOLOGY;

EID: 0141841801     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1093/toxsci/kfg197     Document Type: Review

References (102)

1. Aardema, M. J., and MacGregor, J. T. (2002). Toxicology and genetic toxicology in the new era of "toxicogenomics" Impact of "-omics" technologies. Mutat. Res. 499, 13-25.
2. Anderson, N. L., Matheson, A. D., and Steiner, S. (2000). Proteomics: Applications in basic and applied biology. Curr. Opin. Biotechnol. 11, 408-412.
3. Apple, F. S., and Wu, A. H. B. (2001). Myocardial infarction redefined: Role of cardiac troponin testing. Clin. Chem. 47, 377-379.
4. Ashton, G. H., McGrath, J. A., and South, A. P. (2002). Strategies to identify disease genes. Drugs Today (Barc.) 38, 235-244.
5. Auerbach, C., and Robson, J. M. (1946). Chemical production of mutations. Nature 157, 302.
6. Avery, O. T., McLeod, C. M., and McCarty, M. (1944). Studies on the chemical nature of the substance inducing transformation of Pneumococcal types. J. Exp. Med. 79, 137-158.
7. Backman, L., Appelkvist, E. L., Ringden, O., and Dallner, G. (1988). Glutathione transferase in the urine: A marker for post-transplant tubular lesions. Kidney Int. 33, 571-577.
8. Balmain, A., Gray, J., and Ponder, B. (2003). The genetics and genomics of cancer. Nat. Genet. 33(Suppl.), 238-244.
9. Barnes, J. M., and Denz, F. A. (1954). Experimental methods used in determining chronic toxicity. Pharm. Rev. 6, 191-242.
10. Bichsel, V. E., Liotta, L. A., and Petricoin, E. F., III (2001). Cancer proteomics: From biomarker discovery to signal pathway profiling. Cancer J. 7, 69-78.
11. Blankenberg, F. G., Katsikis, P. D., Tait, J. F., Davis, R. E., Naumovski, L., Ohtsuki, K., Kopiwoda, S., Abrams, M. J., and Strauss, H. W. (1999). Imaging of apoptosis (programmed cell death) with 99mTc annexin V. J. Nucl. Med. 40, 184-191.
12. Borish, L. C., and Steinke, J. W. (2003). Cytokines and chemokines. J. Allergy Clin. Immunol. 111, 460-475.
13. Botstein, D., and Risch, N. (2003). Discovering genotypes underlying human phenotypes: Past successes for mendelian disease, future approaches for complex disease. Nat. Genet. 33(Suppl.), 228-237.
14. Brown, V. M., Ossadtchi, A., Khan, A. H., Cherry, S. R., Leahy, R. M., and Smith, D. J. (2002). High-throughput imaging of brain gene expression. Genome Res. 12, 244-254.
15. Buetow, K. H., Edmonson, M., MacDonald, R., Clifford, R., Yip, P., Kelley, J., Little, D. P., Strausberg, R., Koester, H., Cantor, C. R., et al. (2001). High-throughput development and characterization of a genome wide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc. Natl. Acad. Sci. U.S.A. 98, 581-584.
16. Bullock, G., and Petrusz, P. (1986). Techniques in Immunochemistry, Vol. 1. Academic Press, New York.
17. Cahill, D. J. (2001). Protein and antibody arrays and their medical applications. J. Immunol. Methods 250, 81-91.
18. Cantor, C. R. (1999). Pharmacogenetics becomes pharmacogenomics: Wake up and get ready. Molec. Diag. 4, 287-288.
19. Cantor, C. R. (2000). Biotechnology in the 21st century. Trends Biotechnol. 18, 6-7.
20. +1 lymphoblasts, genetically engineered for expression of cytochromes P450. Toxicology 82, 89-104.
21. Crespi, C. L., and Penman, B. W. (1997). Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Adv. Pharmacol. 43, 171-188.
22. Dawson, E., Abecasis, G. R., Bumpstead, S., Chen, Y., Hunt, S., Beare, D. M., Pabial, J., Dibling, T., Tinsley, E., Kirby, S., et al. (2002). A first-generation disequilibrium map of human chromosome 22. Nature 418, 544-548.
23. DeGeorge, J. (1998). Carcinogenicity testing: A new approach. In Proceeding of the 4th International Conference on Harmonisation, Brussels, 1997 (P. F. D'Arcy and D. W. G. Harron, Eds.), pp. 261-263. Greystone Books, Antrim, N. Ireland.
24. De La Vega, F. M., Dailey, D., Ziegle, J., Williams, J., Madden, D., and Gilbert, D. A. (2002). New generation pharmacogenomic tools: A SNP linkage disequilibrium map, validated SNP assay resource, and high-throughput instrumentation system for large-scale genetic studies. Biotechniques (June Suppl.), 48-50, 52, 54.
25. Department of Health Education and Welfare (1977). Approaches to determining the mutagenic properties of chemicals: Risk to future generations, Committee to Coordinate Toxicology and Related Programs, Subcommittee on Environmental Mutagenesis, 1-58.
26. +- mouse model for detecting in vivo mutation in an endogenous, autosomal gene. Mutat. Res. 423, 125-136.
27. Dukan, S., Farewell, A., Ballestros, M., Taddei, F., Radman, M., and Nyström, T. (2000). Protein oxidation in response to increased transcriptional or translational errors. Proc. Natl. Acad. Sci. U.S.A. 97, 5747-5749.
28. Fabry, M. E. (1993). Transgenic animal models of sickle cell disease. Experientia 49, 28-36.
29. Federal Register (2003). Notice of availability and opportunity to provide comment on the draft final guidelines for carcinogen risk assessment and the draft supplemental guidance for assessing cancer susceptibility from early-life exposure to carcinogens. Fed. Regist. 68(41), 10012-10015.
30. Frank, R. A. and Hargreaves, R. (in press). Clinical biomarkers in drug development. Nat. Rev. & Drug Disc.
31. Gonzalez, F. J. (2002). Transgenic models in xenobiotic metabolism and toxicology. Toxicology 181, 237-239.
32. Goodman, N. (2002). SNPs: Living HapMappily ever after. Genome Technol. (27, 11.02), 46-49.
33. Hamadeh, H. K., Bushel, P. R., Jayadev, S., Martin, K., DiSorbo, O., Sieber, S., Bennett, L., Tennant, R., Stoll, R., Barrett, J. C., et al. (2002). Gene expression analysis reveals chemical-specific profiles. Toxicol. Sci. 67, 219-231.
34. Heddle, J. A., Dean, S., Nohmi, T., Boerrigter, M., Casciano, D., Douglas, G. R., Glickman, B. W., Gorelick, N. G., Mirsalis, J. C., Martus, H. J., et al. (2000). In vivo transgenic mutation assays. Environ. Mol. Mutagen. 35, 253-259.
35. Herman, E. H., Zhang, J., Lipshultz, S. E., Rifai, N., Chadwick, D., Takeda, K., Yu, Z. X., and Ferrans, V. J. (1999). Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J. Clin. Oncol. 17, 2237-2243.
36. Hermann, P. C., Liotta, L. A., and Petricoin, E. F., III (2001). Cancer proteomics: The state of the art. Dis. Markers 17, 49-57.
37. Herschman, H. R., MacLaren, D. C., Iyer, M., Namavari, M., Bobinski, K., Green, L. A., Wu, L., Berk, A. J., Toyokuni, T., Barrio, J. R., et al.. (2000). Seeing is believing: Non-invasive, quantitative and repetitive imaging of reporter gene expression in living animals, using positron emission tomography. J. Neurosci. Res. 59, 699-705.
38. Hoffmann, G. R. (1996). Genetic toxicology. In Casarett & Doull's Toxicology: The Basic Science of Poisons (C. D. Klassen, M. O. Amdur, and J. Doull, Eds.), pp. 269-300. McGraw-Hill, New York.
39. Holt, L. J., Enever, C., deWildt, R. M., and Tomlinson, I. M. (2000). The use of recombinant antibodies in proteomics. Curr. Opin. Biotechnol. 11, 445-449.
40. Huang, R.-P. (2001). Detection of multiple proteins in an antibody-based protein array system. J. Immunol. Methods 255, 1-13.
41. Huang, R.-P., Huang, R., Fan, Y., and Lin, Y. (2001). Simultaneous detection of multiple cytokines from conditioned media and patients sera by an antibody-based protein array system. Anal. Biochem. 294, 55-62.
42. Hughes, T. R., Marton, M. J., Jones, A. R., Roberts, C. J., Stoughton, R., Armour, C. D., Bennett, H. A., Coffey, E., Dai, H., He, Y. D., et al.. (2000). Functional discovery via a compendium of expression profiles. Cell 102, 109-126.
43. Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) (1997). Validation and regulatory acceptance of toxicological test methods: A report of the ad hoc Interagency Coordinating Committee on the Validation of Alternative Methods. NIH Publication No. 97-3981. National Institute of Environmental Health Sciences, Research Triangle Park, NC. Available at http://iccvam.niehs.nih.gov/docs/guidelines/validate.pdf.
44. Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) (1999). Evaluation of the validation status of toxicological methods: general guidelines for submissions to ICCVAM, NIH Publication No. 99-4496, National Institute of Environmental Health Sciences, Research Triangle Park, NC. Available at http://iccvam.niehs.nih.gov/doc1.htm.
45. ICH Harmonised Tripartite Guideline: Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals (1998). In Proc. Fourth Int. Conf. on Harmonisation of Tech. Requirements for Registration of Pharmaceuticals for Human Use (P. F. D'Arcy and D. W. G. Harron, Eds.), pp. 1057-1066. Greystone Books, Antrim, Ireland.
46. Jelinsky, S. A., Estep, P., Church, G. M., and Samson, L. D. (2000). Regulatory networks revealed by transcriptional profiling of damaged Saccharomyces cerevisciae cells: Rpn4 links base excision repair with proteasomes. Mol. Cell. Biol. 20, 8157-8167.
47. Jones, M. B., Krutzsch, H., Zhao, Y., Liotta, L., Kohn, E. C., and Petricoin, E. F., III (2002). Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2, 76-84.
48. Kalow, W. (1965). Contribution of hereditary factors to the response to drugs. Fed. Proc. 24, 1259-1265.
49. Kalow, W. (1968). Drug metabolism enzymes: Pharmacogenetics in animals and man. Ann. N.Y. Acad. Sci. 151, 694-698.
50. Kilty, C., Doyle, S., Hassettt, B., and Manning, F. (1998). Glutathione S-transferases as biomarkers of organ damage: Applications of rodent and canine GST enzyme immunoassays. Chem. Biol. Interact. 111-112, 123-135.
51. Larsen L. A., Andersen, P. S., Kanters, J., Svendsen, I. H., Jacobsen, J. R., Vuust, J., Wettrell, G., Tranebjaerg, L., Bathen, J., and Christiansen, M. (2001). Screening for mutations and polymorphisms in the genes KCNH2 and KCNE2 encoding the cardiac HERG/MiRP1 ion channel: implications for acquiired and congenital long Q-T syndrome. Clin. Chem. 47, 1390-1395.
52. Lederberg, J., and McCray, A. T. (2001). Ome sweet omics-a genealogical treasury of words. The Scientist 15, 8.
53. Lehman, A. J., Lang, E. P., Woodard, G., Draize, J. H., Fitzhugh, O. G., and Nelson, A. A. (1949). Procedures for the appraisal of the toxicity of chemicals in foods. Food Drug Cosmet. Law 4, 412-434.
54. Lindahl, T., and Wood, D. (1999). Quality control by DNA repair. Science 286, 1897-1905.
55. Lipshultz, S. E., Rifai, N., Sallan, S. E., Lipsitz, S. R., Dalton, V., Sacks, D. B., and Ottlinger, M. E. (1997). Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 96, 2496-2497.
56. MacGregor, J. T. (1994). Environmental mutagenesis: Past and future directions. Environ. Mol. Mutagen. 23(S24), 73-77.
57. MacGregor, J. T., Casciano, D. A., and Müller, L. (2000). Strategies and testing methods for identifying mutagenic risks. Mutat. Res. 455, 3-21.
58. Massoud, T. F., and Gambhir, S. S. (2003). Molecular imaging of living subjects: Seeing fundamental biological processes in a new light. Genes Dev. 17, 545-580.
59. Mirsalis, J. C. Montforte, J. A., and Winegar, R. A. (1995). Transgenic animal models for detection of in vivo mutations. Ann. Rev. Pharmacol. Toxicol. 35, 145-164.
60. Murata, M., Gong, P., Suzuki, K., and Koizumi, S. (1999). Differential metal response and regulation of human heavy metal-inducible genes. J. Cell. Physiol. 180, 105-113.
61. Nakazawa, K., and Ohno, Y. (1999). Block by 5-hydroxytryptamine and apomorphine of recombinant human neuronal nicotinic receptors. Eur. J. Pharmacol. 374, 293-299.
62. Nicholson, J. K., Connelly, J., Lindon, J. C., and Holmes, E. (2002). Metabonomics: A platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. 1, 153-61.
63. Nicholson, J. K., Lindon, J. C., and Holmes, E. (1999). "Metabonomics": Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29, 1181-1189.
64. Nolan, J. P., and Mandy, F. F. (2001). Suspension array technology: New tools for gene and protein analysis. Cell. Molec. Biology 47, 1241-1256.
65. Offer, H., Erez, N., Zurer, I, Tang, X., Milyavsky, M., Goldfinger, N., and Rotter, V. (2002). The onset of p53-dependent DNA repair or apoptosis is determined by the level of accumulated damaged DNA. Carcinogenesis 23, 1025-1032.
66. Olson, T. S., and Ley, K. (2002). Chemokines and chemokine receptors in leukocyte trafficking. Am. J. Physiol., Regul. Interg. Comp. Physiol. 283, R7-R28.
67. Paget, G. E. (Ed.) (1970). Methods in Toxicology. Blackwell Scientific Publications, Oxford.
68. Parkinson, A. (1996). Biotransformation of xenobiotics. In Casarett and Doull's Toxicology: The Basic Science of Poisons, 5th ed. (C. D. Klassen,, M. O. Amdur, and J. Doull, Eds.), pp. 113-186. McGraw-Hill, New York.
69. -7 by combining two genotypic selection methods, MutEx enrichment and allele-specific competitive blocker PCR. Environ. Mol. Mutagen. 32, 200-211.
70. Paulmurugan, R., Umezawa, Y., and Gambhir, S.S. (2002). Noninvasive imaging of protein-protein interactions in living subjects by using reporter protein complementation and reconstitution stategies. Proc. Soc. Natl. Acad. Sci. U.S.A. 99, 15608-15613.
71. Pinkus, R., Weiner, L. M., and Daniel, V. (1996). Role of oxidants and antioxidants in the induction of AP-1, NF-kappaB, and glutathione S-transerase gene expression. J. Biol. Chem. 271, 13422-13429.
72. Polak, W. P., Kosieradzki, M., Kwaitkowski, A., Danielewicz, R., Lisik, W., Michalak, G., Paczek, L., Lao, M., Walaszewski, J., and Rowinski, W. A. (1999). Activity of glutathione S-transferases in the urine of kidney transplant recipients during the first week after transplantation. Ann. Transplant. 4, 42-45.
73. Ray, P., Wu, A. M., and Gambhir, S. S. (2003). Optical biluminescence and positron emission tomography imaging of a novel fusion reporter gene in tumor xenografts of living mice. Cancer Res. 63, 1160-1165.
74. Reutelingsperger C. P., Dumont, E., Thimister, P. W., van Genderen, H., Kenis, H., van de Eijnde, S., Heidendal, G., and Hofstra, L. (2002). Visualization of cell death in vivo with the annexin A5 imaging protocol. J. Immunol. Methods 265, 123-132.
75. Robertson, D. G., Reily, M. D., Sigler, R. E., Wells, D. F., Paterson, D. A., and Braden, T. K. (2000). Metabonomics: Evaluation of nuclear magnetic resonance (NMR) and pattern recognition technology for rapid in vivo screening of liver and kidney toxicants. Toxicol. Sci. 57, 326-337.
76. Robinson, D. E., and MacDonald, J. S. (2001). Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. Toxicol. Path. 29(Suppl.), 13-19. (And associated special issue of Toxicol. Path. 29(Suppl.), pp. 1-351.)
77. Ronen, A., and Glickman, B. W. (2001). Human DNA repair genes. Environ. Mol. Mutagen. 37, 241-283.
78. Roses, A. D. (2001). 2025: The practice of neurology-back from the future. Arch. Neurol. 58, 1766-1767.
79. Roses, A. D. (2002). Genome-based pharmacogenetics and the pharmaceutical industry. Nat. Rev. Drug Discov. 1, 541-549.
80. Rudin, M., and Wiessleder, R. (2003). Molecular imaging in drug discovery and development. Nat. Rev. Drug Discov. 2, 123-131.
81. Stambrook, P. J., Shao, C., Stockelman, M., Bovin, G., Engel, S. J., and Tishfield, J. A. (1996). APRT: A versatile in vivo resident reporter of local mutation and loss of heterozygosity. Environ. Mol. Mutagen. 28, 471-482.
82. Steiner, S., and Anderson, N. L. (2000). Pharmaceutical proteomics. Ann. N.Y. Acad. Sci. 919, 48-51.
83. Stumpf, M. P. (2002). Haplotype diversity and the block structure of linkage disequilibrium. Trends Genet. 18, 226-228.
84. Taddei, F., Hayakawa, H., Bouton, M.-F., Cirinesi, A.-M., Matic, I., Sekiguchi, M., and Radman, M. (1997). Counteraction by MutT protein of transcriptional errors caused by oxidative damage. Science 278, 128-130.
85. Tang, J. Y., Hwang, B. J., Ford, J. M., Hanawalt, P. C., and Chu, G. (2000). Xeroderma pigmentosum p48 gene enhances global genomic repair and suppresses UV-induced mutagenesis. Mol. Cell 5, 737-744.
86. Thiry, M. (1992). Highly sensitive immunodetection of DNA on sections with exogenous terminal dioxynucleotidyl transferse and non-isotopic nucleotide analogs. J. Histochem. Cytochem. 40, 411-419.
87. Trull, A. K., Facey, S. P., Rees, G. W., Wight, A. G., Noble-Jamieson, G., Joughin, C., Friend, P. J., and Alexander, G. J. (1994). Serum α-glutathione S-transferase-a sensitive marker of hepatocellular damage associated with acute liver allograft rejection. Transplantation 58, 1345-1351.
88. Ulrich, R., and Friend, S. H. (2002). Toxicogenomics and drug discovery: Will new technologies help us produce better drugs? Nat. Rev. Drug Discov. 1, 84-88.
89. U.S. Food and Drug Administration (2001). Toxicological Principles for the Safety of Food Ingredients, Center for Food Safety and Applied Nutrition (Electronic Redbook 2000, FDA Food Additives Guidance), www.cfsan. fda.gov/∼redbook/red-toca.html.
90. van Engeland, M., Nieland, L. J. W., Ramaekers, F. C. S., Schutte, B., and Reutelingsperger, C. P. M. (1998). Annexin V-affinity assay: A review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 31, 1-9.
91. Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001). The sequence of the human genome. Science 291, 1304-1351.
92. Watson, J. D., Hopkins, N. H., Roberts, J. W., Steitz, J. A., and Weiner, A. M. (1987). The mutability and repair of DNA. In Molecular Biology of the Gene, Vol. 2, pp. 339-357. Benjamin/Cummings, Menlo Park, CA.
93. Weber, W. W. (1999). Populations and genetic polymorphisms. Mol. Diagn. 4, 299-307.
94. Weber, W. W. (2001). Effect of pharmacogenetics on medicine. Environ. Mol. Mutagen. 37, 179-184.
95. Wickner, S., Maurizi, M. R., and Gottesman, S. (1999). Posttranslational quality control: Folding, refolding, and degrading proteins. Science 286, 1888-1893.
96. Wijhoven, S. W., van Sloun, P. P., Kool, H. J., Weeda, G., Slater, R., Lohman, P. H., van Zeeland, A. A., and Vrieling, H. (1998). Carcinogen-induced loss of heterozygosity at the Aprt lous of somatic cells in the mouse. Proc. Natl. Acad. Sci. U.S.A. 95, 13759-13764.
97. Wijsman, J. H., Jonker, R. R., Keijzer, R., van de Velde, C. J., Cornelisse, C. J. and van Dierendonck, J. H. (1993). A new method to detect apoptosis in paraffin sections: In situ end-labeling of fragmented DNA. J. Histochem. Cytochem. 41, 7-12.
98. Wilson, L., Taylor, D., and Wang, Y.-L. (1990). Fluorescence Microscopy of Living Cells in Culture, Part B: Quantitative Fluorescence Microscopy-Imaging and Spectroscopy, Methods in Cell Biology, Vol. 30. Academic Press, New York.
99. Wolters, D. A., Washburn, M. P., and Yates, J. R., III. (2001). An automated multidimensional protein identification technology for shotgun proteomics. Anal. Chem. 73, 5683-5690.
100. Yates, Y. R., III. (1998). Mass spectrometry and the age of the proteome. J. Mass Spectrom. 33, 1-19.
101. Yates, Y. R., III. (2000). Mass spectrometry. From genomics to proteomics. Trends Genet. 16, 5-8.
102. Zola, H. (1992). Phenotypic markers for functional lymphocyte populations: A critical appraisal of current usage as disease markers and future prospects. Dis. Markers 10, 53-66.